PAR — Paradigm Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$161.61m
- AU$137.02m
- AU$6.52m
- 63
- 17
- 69
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.75 | ||
| Price to Tang. Book | 5.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 28.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.65% | ||
| Return on Equity | -46.04% | ||
| Operating Margin | -275.49% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.65 | 8.58 | 7.89 | 8.49 | 6.52 | 3 | n/a | 14.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
Directors
- Paul Rennie NEC
- Donna Skerrett CEO
- Kevin Hollingsworth SEC (68)
- Helen Fisher NID
- John Gaffney NID
- Amos Meltzer NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 2nd, 2014
- Public Since
- August 19th, 2015
- No. of Shareholders
- 13,758
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 389,428,603
- Address
- Level 15, 500 Collins St, MELBOURNE, 3000
- Web
- https://paradigmbiopharma.com/
- Phone
- +61 396295566
- Auditors
- RSM Australia Partners
Upcoming Events for PAR
Paradigm Biopharmaceuticals Ltd Annual Shareholders Meeting
Similar to PAR
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Paradigm Biopharmaceuticals share price?
As of Today at 04:33 UTC, shares in Paradigm Biopharmaceuticals are trading at AU$0.42. This share price information is delayed by 15 minutes.
How has the Paradigm Biopharmaceuticals share price performed this year?
Shares in Paradigm Biopharmaceuticals last closed at AU$0.42 and the price had moved by +50.91% over the past 365 days. In terms of relative price strength the Paradigm Biopharmaceuticals share price has outperformed the ASX All Ordinaries Index by +39.16% over the past year.
What are the analyst and broker recommendations for Paradigm Biopharmaceuticals?
The overall consensus recommendation for Paradigm Biopharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Paradigm Biopharmaceuticals dividend yield?
Paradigm Biopharmaceuticals does not currently pay a dividend.
Does Paradigm Biopharmaceuticals pay a dividend?
Paradigm Biopharmaceuticals does not currently pay a dividend.
When does Paradigm Biopharmaceuticals next pay dividends?
Paradigm Biopharmaceuticals does not currently pay a dividend.
How do I buy Paradigm Biopharmaceuticals shares?
To buy shares in Paradigm Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Paradigm Biopharmaceuticals?
As of the previous close price of AU$0.42, shares in Paradigm Biopharmaceuticals had a market capitalisation of AU$161.61m.
Where are Paradigm Biopharmaceuticals shares listed?
Here are the trading details for Paradigm Biopharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PAR
What kind of share is Paradigm Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum Paradigm Biopharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Paradigm Biopharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Paradigm Biopharmaceuticals is AU$0.73. That is 75.9% above the last closing price of AU$0.42.
Analysts covering Paradigm Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.03 for the next financial year.
Find out moreWhat is the trend in the Paradigm Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Paradigm Biopharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -5.54%.
As of the last closing price of AU$0.42, shares in Paradigm Biopharmaceuticals were trading +15.66% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Paradigm Biopharmaceuticals PE Ratio?
The Paradigm Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Paradigm Biopharmaceuticals?
Paradigm Biopharmaceuticals' management team is headed by:
- Paul Rennie - NEC
- Donna Skerrett - CEO
- Kevin Hollingsworth - SEC
- Helen Fisher - NID
- John Gaffney - NID
- Amos Meltzer - NID